1.Huggins AB, Carrasco JR, Eagle RC. MEN 2B masquerading as chronic blepharitis and euryblepharon. Orbit. 2019 Dec;38(6):514-518. [PubMed]
2.Rodriguez-Garcia A, Loya-Garcia D, Hernandez-Quintela E, Navas A. Risk factors for ocular surface damage in Mexican patients with dry eye disease: a population-based study. Clin Ophthalmol. 2019;13:53-62. [PMC free article] [PubMed]
3.Choi FD, Juhasz MLW, Atanaskova Mesinkovska N. Topical ketoconazole: a systematic review of current dermatological applications and future developments. J Dermatolog Treat. 2019 Dec;30(8):760-771. [PubMed]
4.Ozkan J, Willcox MD. The Ocular Microbiome: Molecular Characterisation of a Unique and Low Microbial Environment. Curr Eye Res. 2019 Jul;44(7):685-694. [PubMed]
5.Khoo P, Ooi KG, Watson S. Effectiveness of pharmaceutical interventions for meibomian gland dysfunction: An evidence-based review of clinical trials. Clin Exp Ophthalmol. 2019 Jul;47(5):658-668. [PubMed]
6.Soh Qin R, Tong Hak Tien L. Healthcare delivery in meibomian gland dysfunction and blepharitis. Ocul Surf. 2019 Apr;17(2):176-178. [PubMed]
7.Fromstein SR, Harthan JS, Patel J, Opitz DL. Demodex blepharitis: clinical perspectives. Clin Optom (Auckl). 2018;10:57-63. [PMC free article] [PubMed]
8.Pflugfelder SC, Karpecki PM, Perez VL. Treatment of blepharitis: recent clinical trials. Ocul Surf. 2014 Oct;12(4):273-84. [PubMed]
9.Kanda Y, Kayama T, Okamoto S, Hashimoto M, Ishida C, Yanai T, Fukumoto M, Kunihiro E. Post-marketing surveillance of levofloxacin 0.5% ophthalmic solution for external ocular infections. Drugs R D. 2012 Dec 01;12(4):177-85. [PMC free article] [PubMed]
10.Veldman P, Colby K. Current evidence for topical azithromycin 1% ophthalmic solution in the treatment of blepharitis and blepharitis-associated ocular dryness. Int Ophthalmol Clin. 2011 Fall;51(4):43-52. [PubMed]
11.Hosseini K, Bourque LB, Hays RD. Development and evaluation of a measure of patient-reported symptoms of Blepharitis. Health Qual Life Outcomes. 2018 Jan 11;16(1):11. [PMC free article] [PubMed]